Literature DB >> 16973751

Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.

Ngoc-Quynh-Nhu Nguyen1, Sebastien P Tabruyn, Laurence Lins, Michelle Lion, Anne M Cornet, Florence Lair, Francoise Rentier-Delrue, Robert Brasseur, Joseph A Martial, Ingrid Struman.   

Abstract

Angiogenesis is a crucial step in many pathologies, including tumor growth and metastasis. Here, we show that tilted peptides exert antiangiogenic activity. Tilted (or oblique-oriented) peptides are short peptides known to destabilize membranes and lipid cores and characterized by an asymmetric distribution of hydrophobic residues along the axis when helical. We have previously shown that 16-kDa fragments of the human prolactin/growth hormone (PRL/GH) family members are potent angiogenesis inhibitors. Here, we demonstrate that all these fragments possess a 14-aa sequence having the characteristics of a tilted peptide. The tilted peptides of human prolactin and human growth hormone induce endothelial cell apoptosis, inhibit endothelial cell proliferation, and inhibit capillary formation both in vitro and in vivo. These antiangiogenic effects are abolished when the peptides' hydrophobicity gradient is altered by mutation. We further demonstrate that the well known tilted peptides of simian immunodeficiency virus gp32 and Alzheimer's beta-amyloid peptide are also angiogenesis inhibitors. Taken together, these results point to a potential new role for tilted peptides in regulating angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16973751      PMCID: PMC1599962          DOI: 10.1073/pnas.0606638103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  39 in total

1.  Molecular determinants of the interaction between the C-terminal domain of Alzheimer's beta-amyloid peptide and apolipoprotein E alpha-helices.

Authors:  L Lins; A Thomas-Soumarmon; T Pillot; J Vandekerchkhove; M Rosseneu; R Brasseur
Journal:  J Neurochem       Date:  1999-08       Impact factor: 5.372

2.  The antiangiogenic factor, 16-kDa human prolactin, induces endothelial cell cycle arrest by acting at both the G0-G1 and the G2-M phases.

Authors:  Sébastien P Tabruyn; Ngoc-Quynh-Nhu Nguyen; Anne M Cornet; Joseph A Martial; Ingrid Struman
Journal:  Mol Endocrinol       Date:  2005-03-03

Review 3.  Angiogenesis in life, disease and medicine.

Authors:  Peter Carmeliet
Journal:  Nature       Date:  2005-12-15       Impact factor: 49.962

4.  Solution structure of human prolactin.

Authors:  Kaare Teilum; Jeffrey C Hoch; Vincent Goffin; Sandrina Kinet; Joseph A Martial; Birthe B Kragelund
Journal:  J Mol Biol       Date:  2005-08-26       Impact factor: 5.469

5.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

Authors:  I Struman; F Bentzien; H Lee; V Mainfroid; G D'Angelo; V Goffin; R I Weiner; J A Martial
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

6.  Computational study of lipid-destabilizing protein fragments: towards a comprehensive view of tilted peptides.

Authors:  L Lins; B Charloteaux; A Thomas; R Brasseur
Journal:  Proteins       Date:  2001-09-01

7.  Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action.

Authors:  V Jouan; X Canron; M Alemany; J P Caen; G Quentin; J Plouet; A Bikfalvi
Journal:  Blood       Date:  1999-08-01       Impact factor: 22.113

8.  Cell surface glypicans are low-affinity endostatin receptors.

Authors:  S A Karumanchi; V Jha; R Ramchandran; A Karihaloo; L Tsiokas; B Chan; M Dhanabal; J I Hanai; G Venkataraman; Z Shriver; N Keiser; R Kalluri; H Zeng; D Mukhopadhyay; R L Chen; A D Lander; K Hagihara; Y Yamaguchi; R Sasisekharan; L Cantley; V P Sukhatme
Journal:  Mol Cell       Date:  2001-04       Impact factor: 17.970

9.  Inhibition of urokinase activity by the antiangiogenic factor 16K prolactin: activation of plasminogen activator inhibitor 1 expression.

Authors:  H Lee; I Struman; C Clapp; J Martial; R I Weiner
Journal:  Endocrinology       Date:  1998-09       Impact factor: 4.736

10.  16K human prolactin inhibits vascular endothelial growth factor-induced activation of Ras in capillary endothelial cells.

Authors:  G D'Angelo; J F Martini; T Iiri; W J Fantl; J Martial; R I Weiner
Journal:  Mol Endocrinol       Date:  1999-05
View more
  11 in total

1.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

2.  Small peptides derived from somatotropin domain-containing proteins inhibit blood and lymphatic endothelial cell proliferation, migration, adhesion and tube formation.

Authors:  Esak Lee; Elena V Rosca; Niranjan B Pandey; Aleksander S Popel
Journal:  Int J Biochem Cell Biol       Date:  2011-09-06       Impact factor: 5.085

3.  Inhibitory activity of the peptides derived from buffalo prolactin on angiogenesis.

Authors:  Jaeok Lee; Syamantak Majumder; Suvro Chatterjee; Kambadur Muralidhar
Journal:  J Biosci       Date:  2011-06       Impact factor: 1.826

Review 4.  Diabetic retinopathy and pregnancy.

Authors:  Nicola Pescosolido; Orazio Campagna; Andrea Barbato
Journal:  Int Ophthalmol       Date:  2014-01-31       Impact factor: 2.031

5.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

6.  A novel peptide from human apolipoprotein(a) inhibits angiogenesis and tumor growth by targeting c-Src phosphorylation in VEGF-induced human umbilical endothelial cells.

Authors:  Zheng-Fang Yi; Sung-Gook Cho; Hui Zhao; Yuan-Yuan Wu; Jian Luo; Dali Li; Tingfang Yi; Xun Xu; Zirong Wu; Mingyao Liu
Journal:  Int J Cancer       Date:  2009-02-15       Impact factor: 7.396

7.  STAT5 and prolactin participate in a positive autocrine feedback loop that promotes angiogenesis.

Authors:  Xinhai Yang; Kristy Meyer; Andreas Friedl
Journal:  J Biol Chem       Date:  2013-06-02       Impact factor: 5.157

8.  Sprouty1, a new target of the angiostatic agent 16K prolactin, negatively regulates angiogenesis.

Authors:  Céline Sabatel; Anne M Cornet; Sébastien P Tabruyn; Ludovic Malvaux; Karolien Castermans; Joseph A Martial; Ingrid Struman
Journal:  Mol Cancer       Date:  2010-09-02       Impact factor: 27.401

9.  Vasoinhibin comprises a three-helix bundle and its antiangiogenic domain is located within the first 79 residues.

Authors:  Juan Pablo Robles; Magdalena Zamora; José Luis Velasco-Bolom; Miriam Tovar; Ramón Garduño-Juárez; Thomas Bertsch; Gonzalo Martínez de la Escalera; Jakob Triebel; Carmen Clapp
Journal:  Sci Rep       Date:  2018-11-20       Impact factor: 4.379

Review 10.  NF-kappa B: a new player in angiostatic therapy.

Authors:  Sebastien P Tabruyn; Arjan W Griffioen
Journal:  Angiogenesis       Date:  2008-02-19       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.